Prothena Corporation plc Logo

Email this page: News Release

Prothena to Present Clinical Results From its Phase 1 Single Ascending Dose Study of PRX003, an Anti-MCAM Antibody Being Investigated for Inflammatory Diseases, at EULAR 2016

For security reasons, registration is required before you can use this feature.
* Indicates required field